PL1653964T3 - Skojarzone leczenie raka obejmujące AZD2171 i ZD1839 - Google Patents
Skojarzone leczenie raka obejmujące AZD2171 i ZD1839Info
- Publication number
- PL1653964T3 PL1653964T3 PL04743287T PL04743287T PL1653964T3 PL 1653964 T3 PL1653964 T3 PL 1653964T3 PL 04743287 T PL04743287 T PL 04743287T PL 04743287 T PL04743287 T PL 04743287T PL 1653964 T3 PL1653964 T3 PL 1653964T3
- Authority
- PL
- Poland
- Prior art keywords
- azd2171
- human
- combination therapy
- cancer
- antiangiogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316127.0A GB0316127D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
EP04743287A EP1653964B1 (en) | 2003-07-10 | 2004-07-08 | Cancer combination therapy comprising azd2171 and zd1839 |
PCT/GB2004/002944 WO2005004872A1 (en) | 2003-07-10 | 2004-07-08 | Cancer combination therapy comprising azd2171 and zd1839 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1653964T3 true PL1653964T3 (pl) | 2009-01-30 |
Family
ID=27741907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04743287T PL1653964T3 (pl) | 2003-07-10 | 2004-07-08 | Skojarzone leczenie raka obejmujące AZD2171 i ZD1839 |
Country Status (24)
Country | Link |
---|---|
US (2) | US20060167024A1 (pl) |
EP (1) | EP1653964B1 (pl) |
JP (1) | JP2007526888A (pl) |
KR (1) | KR20060033785A (pl) |
CN (1) | CN100415236C (pl) |
AT (1) | ATE409039T1 (pl) |
AU (1) | AU2004255024B2 (pl) |
BR (1) | BRPI0412408A (pl) |
CA (1) | CA2531620C (pl) |
DE (1) | DE602004016754D1 (pl) |
DK (1) | DK1653964T3 (pl) |
ES (1) | ES2313033T3 (pl) |
GB (1) | GB0316127D0 (pl) |
HK (1) | HK1089667A1 (pl) |
HR (1) | HRP20080597T3 (pl) |
IL (1) | IL172683A0 (pl) |
MX (1) | MXPA06000412A (pl) |
NO (1) | NO20056170L (pl) |
NZ (1) | NZ544270A (pl) |
PL (1) | PL1653964T3 (pl) |
PT (1) | PT1653964E (pl) |
SI (1) | SI1653964T1 (pl) |
WO (1) | WO2005004872A1 (pl) |
ZA (1) | ZA200600184B (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
NZ549552A (en) * | 2004-03-23 | 2009-12-24 | Astrazeneca Ab | Combination therapy involving 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (AZD2171) and a platinum anti-tumour agent |
GB0406445D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
EP1901754A2 (en) * | 2005-07-06 | 2008-03-26 | AstraZeneca AB | Combination therapy of cancer with azd2171 and gemcitabine |
US20080306094A1 (en) * | 2005-12-22 | 2008-12-11 | Stephen Robert Wedge | Combination of Azd2171 and Pemetrexed |
WO2009118560A1 (en) * | 2008-03-28 | 2009-10-01 | Astrazeneca Ab | Combination therapy 038 |
EP2113255A1 (en) * | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU762615B2 (en) * | 1998-06-15 | 2003-07-03 | Arch Development Corporation | Combination of radiotherapy and anti-angiogenic factors |
AU763618B2 (en) * | 1999-02-10 | 2003-07-31 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors |
NZ534190A (en) * | 2000-03-31 | 2007-05-31 | Angiogene Pharm Ltd | Divided dose therapies with vascular damaging activity |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
AU2002223684A1 (en) * | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
RU2365588C2 (ru) * | 2002-02-01 | 2009-08-27 | Астразенека Аб | Хиназолиновые соединения |
-
2003
- 2003-07-10 GB GBGB0316127.0A patent/GB0316127D0/en not_active Ceased
-
2004
- 2004-07-08 SI SI200430923T patent/SI1653964T1/sl unknown
- 2004-07-08 US US10/563,439 patent/US20060167024A1/en not_active Abandoned
- 2004-07-08 AU AU2004255024A patent/AU2004255024B2/en not_active Ceased
- 2004-07-08 EP EP04743287A patent/EP1653964B1/en not_active Expired - Lifetime
- 2004-07-08 MX MXPA06000412A patent/MXPA06000412A/es active IP Right Grant
- 2004-07-08 DE DE602004016754T patent/DE602004016754D1/de not_active Expired - Lifetime
- 2004-07-08 WO PCT/GB2004/002944 patent/WO2005004872A1/en active IP Right Grant
- 2004-07-08 PT PT04743287T patent/PT1653964E/pt unknown
- 2004-07-08 CN CNB200480019517XA patent/CN100415236C/zh not_active Expired - Fee Related
- 2004-07-08 AT AT04743287T patent/ATE409039T1/de active
- 2004-07-08 NZ NZ544270A patent/NZ544270A/en not_active IP Right Cessation
- 2004-07-08 DK DK04743287T patent/DK1653964T3/da active
- 2004-07-08 JP JP2006518355A patent/JP2007526888A/ja active Pending
- 2004-07-08 ES ES04743287T patent/ES2313033T3/es not_active Expired - Lifetime
- 2004-07-08 KR KR1020067000533A patent/KR20060033785A/ko active IP Right Grant
- 2004-07-08 PL PL04743287T patent/PL1653964T3/pl unknown
- 2004-07-08 CA CA2531620A patent/CA2531620C/en not_active Expired - Fee Related
- 2004-07-08 BR BRPI0412408-1A patent/BRPI0412408A/pt not_active IP Right Cessation
-
2005
- 2005-12-19 IL IL172683A patent/IL172683A0/en unknown
- 2005-12-23 NO NO20056170A patent/NO20056170L/no not_active Application Discontinuation
-
2006
- 2006-01-09 ZA ZA200600184A patent/ZA200600184B/en unknown
- 2006-09-11 HK HK06110069.9A patent/HK1089667A1/xx not_active IP Right Cessation
-
2008
- 2008-11-19 HR HR20080597T patent/HRP20080597T3/xx unknown
-
2009
- 2009-09-08 US US12/555,592 patent/US20100179142A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1653964T3 (da) | 2009-01-05 |
ZA200600184B (en) | 2007-04-25 |
EP1653964A1 (en) | 2006-05-10 |
CN1819831A (zh) | 2006-08-16 |
PT1653964E (pt) | 2008-11-24 |
WO2005004872A1 (en) | 2005-01-20 |
GB0316127D0 (en) | 2003-08-13 |
US20060167024A1 (en) | 2006-07-27 |
CN100415236C (zh) | 2008-09-03 |
EP1653964B1 (en) | 2008-09-24 |
AU2004255024B2 (en) | 2007-09-27 |
ES2313033T3 (es) | 2009-03-01 |
BRPI0412408A (pt) | 2006-08-22 |
HK1089667A1 (en) | 2006-12-08 |
KR20060033785A (ko) | 2006-04-19 |
IL172683A0 (en) | 2006-04-10 |
NO20056170L (no) | 2006-02-08 |
CA2531620C (en) | 2011-09-27 |
MXPA06000412A (es) | 2006-03-17 |
SI1653964T1 (sl) | 2009-02-28 |
NZ544270A (en) | 2007-09-28 |
HRP20080597T3 (en) | 2008-12-31 |
ATE409039T1 (de) | 2008-10-15 |
CA2531620A1 (en) | 2005-01-20 |
US20100179142A1 (en) | 2010-07-15 |
AU2004255024A1 (en) | 2005-01-20 |
JP2007526888A (ja) | 2007-09-20 |
DE602004016754D1 (de) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
EP1971338B8 (en) | Combination of zd6474 and pemetrexed | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
HK1123976A1 (en) | Combination of azd2171 and pemetrexed azd2171 | |
HK1096023A1 (en) | Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11 | |
MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
ZA200600188B (en) | Combination therapy | |
WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent | |
IL177953A0 (en) | Combination therapy including azd2171 and a taxane | |
WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine |